USFDA successfully concludes inspection at Syngene Bangalore facility
Bengaluru: Syngene International Limited has recently announced that the US Food Drug Administration (USFDA) has successfully concluded a pre-approval inspection with Zero 483 observations at the company's Biologics facility in Bangalore.
"This is to inform you that the US Food and Drug Administration (USFDA) has conducted its pre-approval inspection of the Biologics facility at Bangalore from November 07, 2022, till November 15, 2022. The inspection was completed successfully without 483 observations," the company said in a BSE filing.
The inspection was conducted from November 07, 2022, to November 15, 2022.
Read also: Syngene, Zoetis ink pact to manufacture drug substance for Librela
Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. With a combination of research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2 Mn sq. ft of specialist discovery, development, and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis, and Merck KGaA.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd